Osimertinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4302 publications

Research Progress on Circulating Tumor DNA Status and Postoperative Central Nervous System Recurrence Risk and Overall Survival in Non-small Cell Lung Cancer

Research Progress on Circulating Tumor DNA Status and Postoperative Central Nervous System Recurrence Risk and Overall Survival in Non-small Cell Lung Cancer

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: September 07, 2026

Osimertinib-Associated Cardiotoxicity in EGFR-Mutant Non-Small Cell Lung Cancer: Mechanisms, Phenotypes, and Surveillance.

Osimertinib-Associated Cardiotoxicity in EGFR-Mutant Non-Small Cell Lung Cancer: Mechanisms, Phenotypes, and Surveillance.

Journal: Cardiology in review

Published: August 24, 2026

Holmes tremor as the initial manifestation of EGFR mutated lung cancer

Holmes tremor as the initial manifestation of EGFR mutated lung cancer

Journal: Medicina

Published: August 16, 2026

Erratum to 'Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated nonsmall cell lung cancer with brain metastases' [Seminars in Oncology 53/1 (2026) 152436].

Erratum to 'Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated nonsmall cell lung cancer with brain metastases' [Seminars in Oncology 53/1 (2026) 152436].

Journal: Seminars in oncology

Published: August 12, 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary.

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary.

Journal: JAMA

Published: August 10, 2026

DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report.

DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report.

Journal: Internal medicine (Tokyo, Japan)

Published: August 10, 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Journal: JAMA

Published: August 10, 2026

Efficacy and Safety of Savolitinib Plus Osimertinib in EGFR-Mutant, MET-Aberrant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Efficacy and Safety of Savolitinib Plus Osimertinib in EGFR-Mutant, MET-Aberrant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Journal: American journal of clinical oncology

Published: August 09, 2026

Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance.

Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance.

Journal: Science advances

Published: August 05, 2026

Synchronous Follicular Lymphoma and Lung Adenocarcinoma-A Case Report

Synchronous Follicular Lymphoma and Lung Adenocarcinoma-A Case Report

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

Journal: JTO clinical and research reports

Published: July 28, 2026

Beyond the standard 80 mg: Exposure-guided and equity-oriented precision dosing of Osimertinib in EGFR-mutant NSCLC.

Beyond the standard 80 mg: Exposure-guided and equity-oriented precision dosing of Osimertinib in EGFR-mutant NSCLC.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: July 25, 2026

Showing 1-12 of 4,302

Last Updated: 09/26/2026